Day One Biopharmaceuticals (DAWN) Company Total Revenue

Corporate emblem and logo of Day One Biopharmaceuticals, Inc. (DAWN)

Commercial realization volumes for Day One (DAWN) demonstrate a trend where the current status equals 0.16. Growth is accelerating due to AI-driven biomarker screening and test automation. However, stringent FDA requirements and colossal clinical trial costs are hindering development. Business stability is reinforced by retaining leading oncologists through a stock option system, which prevents the loss of key personnel.

DAWN - Day One Biopharmaceuticals Company Revenue over the range 07/04/2022 - 05/09/2026

Analytical breakdowns for Day One Biopharmaceuticals (DAWN)

- stock value and consensus price forecast:
Stock Quotes Day One Biopharmaceuticals Inc|DAWN - Price Target Chart
- market capitalization details:
Market Value Day One|DAWN - Total Company Value
- book value of equity indicators:
Net Assets per Single Share Day One Biopharmaceuticals|DAWN - Company Book Value|Market-to-Book Ratio dayonebio.com|DAWN - Company Total Assets
- company liabilities and liquidity data:
Debt to Capital Ratio Day One|DAWN - Long-Term Debt to Equity Ratio|Current Liabilities to Capital Day One Biopharmaceuticals, Inc.|DAWN - Company Total Debt|Debt to Net Assets Ratio Day One|DAWN - Company Long-Term Liabilities|Amount of Current Liabilities Day One Biopharmaceuticals|Intermediate Coverage Ratio dayonebio.com
- earnings and market ratios statistics:
DAWN - Net Profit|Expected Net Profit Day One|DAWN - Price to Earnings Ratio|Future Price to Earnings Multiple dayonebio.com|DAWN - PEG Multiple|EV/EBITDA Multiple Day One|DAWN - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Day One Biopharmaceuticals|DAWN - Net earnings per share for the last 12 months|Earnings per share growth in annualized terms for the last twelve months dayonebio.com|DAWN - Earnings growth in current year|Projected earnings per share growth rate for next year Day One
- sales volume and revenue indicators:
DAWN - Revenue and Sales Volume|Projected Sales Volume Day One Biopharmaceuticals Inc|DAWN - Market Cap to Revenue|Market Cap to Future Revenue Ratio Day One
General company analysis:Day One Biopharmaceuticals Inc - DAWN
Mass-produced product of Day One

To assess business resilience, it is essential for investors to analyze actual cash flows. This indicator measures real daily receipts from customers, excluding accounting adjustments and accruals. By analyzing the total sales revenue of Day One (DAWN), one can determine the true liquidity and growth rates of the business. A positive trend confirms the commercial viability of Day One. This is critically important when scaling their exclusive pediatric oncology treatment ecosystem.

Competing companies

Company Sales Incyte Pharma (INCY)|Company Revenue HUTCHMED (China) Limited (HCM)|NUVB - Company Total Revenue|Company Revenue Monopar Therapeutics Inc. MNPR|Inhibrx - Company Revenue|IMAB - Company Revenue|Company Total Revenue Fennec|HRTX: Revenue and Sales Volume|Company Total Sales Volume nuvectis.com NVCT|Company Sales CHRS|Company Total Revenue Corbus Pharmaceuticals Holdings, Inc. CRBP|Company Sales CRDF (Cardiff Oncology, Inc.)|BYSI (BeyondSpring Inc) - Company Sales Revenue|BioAtla - Company Sales|Company Total Sales LIXT (lixte.com)|Citius Pharma - Revenue and Sales Volume|Company Sales Revenue CLRB (Cellectar Biosciences Inc)|BLRX: Revenue and Sales Volume|Company Total Revenue Can-Fite (CANF)|Company Revenue Aprea Therapeutics Inc.|KZIA: Company Sales Revenue|Revenue and Sales Volume SLXN|Revenue and Sales Volume nucana.com (NCNA)|Company Revenue Chimerix, Inc CMRX|CYCC (Cyclacel, Inc.) - Company Annual Revenue|GTHX: Company Sales|Company Total Revenue kronosbio.com|KTRA: Revenue and Sales Volume|Company Sales Volume ONCT|PRTG (Portage) - Revenue and Sales Volume